10-Q quarterly report · filed Nov 5, 2026

COLLEGIUM PHARMACEUTICAL, INC (COLL) Q3 2026 10-Q Quarterly Report

Short answer

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $216M (up 3.3% year over year) with net income of $22M.

Q3 2026 key financials · XBRL

Revenue
$216M
+3.3% YoY · +8.2% QoQ
Net income
$22M
−30.9% YoY · +244.6% QoQ
Operating margin
13.3%
Gross margin
58.0%
EPS (diluted)
$0.66
−21.4% YoY · +257.1% QoQ

Source: XBRL data from the COLLEGIUM PHARMACEUTICAL, INC (COLL) Q3 2026 10-Q on SEC EDGAR. USD.

COLLEGIUM PHARMACEUTICAL, INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $216.3M, up $6.9M YoY from $209.4M
  • Operating margin 13.3% vs 29.6% YoY, net margin 10.1% vs 15.0%
  • Best product: Azstarys revenue $26.5M increase; worst: Nucynta Products revenue $24.0M decrease
  • Operating cash flow $215.0M, up from $206.3M; $655.4M Azstarys acquisition payment
  • Cash $144.8M; $50.0M accelerated share repurchase and $300.0M acquisition financing draw

Risk Factors

  • Newly added AI risk: internal and vendor AI use may expose confidential data or create inaccurate outputs, amid evolving U.S. and EU regulation
  • Most materially updated competition risk: Hikma launched Nucynta IR and ER generics on February 25, 2026 and March 11, 2026
  • Regulatory risk: FDA heightened promotional scrutiny in September 2025, increasing challenge risk for Xtampza ER advertising
  • Operational risk: sole manufacturer Patheon supplies Xtampza ER and Nucynta ER, creating disruption exposure
  • Financial risk: $854.5 million term loan plus $241.5 million convertible notes, with floating-rate debt unhedged

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other COLLEGIUM PHARMACEUTICAL, INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.